The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition
Open accessAbstract
Background: The role of both microglial activation and alpha-synuclein deposition in Parkinson's disease remain unclear. We have tested the hypothesis that if microglia play a primary role in Parkinson's disease pathogenesis, the microglial "activated" phenotype should be associated with histopathological and/or clinical features of the disease. Methods: We have examined microglial MHC class II expression, a widely used marker of microglial activation, the occurrence of CD68-positive phagocytes and alpha-synuclein immunoreactivity in post-mortem human substantia nigra affected by idiopathic Parkinson's disease (PD). Using semi-quantitative severity ratings, we have examined the relationship between microglial activation, alpha-synuclein deposition, classical neuropathological criteria for PD, subtype of the disease and clinical course. Results: While we did not observe an association between microglial MHC class II expression and clinical parameters, we did find a correlation between disease duration and the macrophage marker CD68 which is expressed by phagocytic microglia. In addition, we observed a significant correlation between the degree of MHC class II expression and alpha-synuclein deposition in the substantia nigra in PD. Conclusion: While microglia appeared to respond to alpha-synuclein deposition, MHC class II antigen expression by microglia in the substantia nigra cannot be used as an indicator of clinical PD severity or disease progression. In addition, a contributory or even causative role for microglia in the neuronal loss associated with PD as suggested by some authors seems unlikely. Our data further suggest that an assessment of microglial activation in the aged brain on the basis of immunohistochemistry for MHC class II antigens alone should be done with caution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dysregulation of microglia functions contribute to the pathogenesis of neurodegenerative diseases, including Alzheimer’s disease (AD) (6–8), Parkinson’s disease (PD) (9–12) and Huntington’s disease (HD) (13–15).”
From An environment-dependent transcriptional network specifies human microglia identity (2017) · cites this paper as [10]
Experimental — accuracy not yet measuredIn the citing paper
“Microglia accumulate near α-synuclein deposits and become proinflammatory in a manner dependent on receptors that also bind Aβ, such as CD36 and TLR263–65.”
From Microglia in neurodegeneration (2018) · cites this paper as [63]
In the citing paper
“Microglia also phagocytose α-synuclein, the constituent protein of Lewy bodies in Parkinson’s and Lewy Body dementias, and become pro-inflammatory in the process, expressing cytokines (IL1β, IL6, TNFα), reactive oxygen species (ROS) and prostaglandin synthesising cyclooxygenase 2 (COX2) [24,25,26].”
From ROS Generation in Microglia: Understanding Oxidative Stress and Inflammation in Neurodegenerative Disease (2020) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Self-citationMcGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
α-synuclein locus duplication as a cause of familial Parkinson's disease
Chartier-Harlin, M.-C., Kachergus, J., Roumier, C., Mouroux, V., Douay, X., Lincoln, S., Levecque, C., Larvor, L., Andrieux, J., Hulihan, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17103-1 · Cited by 2,029
Liu, B., & Hong, J.-S. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.035048 · Cited by 1,095
Imamura, K., Hishikawa, N., Sawada, M., Nagatsu, T., Yoshida, M., & Hashizume, Y. (2003) · Acta Neuropathologica · doi:10.1007/s00401-003-0766-2 · Cited by 791
Research works printed but not linked: 1
- Graeber MB: Glial inflammation in neurodegenerative diseases. 8th Annual Congress of the British Society for Immunology, Harrogate, 5–8 December 2000, Immunology. 2000, Oxford: Blackwells, Abstract, Supplement
Cited by
Sorted by citations
Items 401–416 of 416
Bathe, T., Hery, G. P., Villareal, J. A. B., Phillips, J. L., Cohen, E. M., Sharma, R. V., Tsering, W., & Prokop, S. (2024) · Figshare · doi:10.6084/m9.figshare.26702593
The effects of bacterial and viral infections on microglia
Ermolina, S., & Bowdish, D. M. E. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27340-7.00001-2
Garland, B., Shen, Z., Chen, M., Gao, B., Mao, K., Richardson, D. R., Mellick, G. D., & Ma, L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.01.708908
Yadav, A., Vacchi, E., Pinton, S., Lazzarini, E., Pecoraro, M., Raimondi, A., Barile, L., Kaelin‐Lang, A., & Melli, G. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.03.10.709299 · Cited by 1
Understanding the role of perivascular macrophages in Parkinson's disease pathophysiology
Fuentealba, J. R. (2017) · theses.fr (ABES) · doi:10.70675/b2e8f905z4f72z497eza017zc5b9d7fe53a1
Étude moléculaire de l'inflammation chronique dans la maladie de Parkinson
Compagnion, A. (2019) · theses.fr (ABES) · doi:10.70675/04ca138dz3131z4e24z884czbba2f7954a99
Yildirim-Balatan, C. (2021) · theses.fr (ABES) · doi:10.70675/3372ff2ez69a6z4970z881bze4dfe0a15571
Microglia crosstalk with T cells in neurodegenerative diseases: pathogenesis and treatment targets
Chen, G., Zhao, C., Wang, C., Chen, G., Shi, J., & Chen, H. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116781
Culicetto, L., Marafioti, G., Bonanno, L., Morabito, R., Fallica, G. E., Sorbera, C., Lorenzo, G. D., Marino, S., Quartarone, A., & Ciurleo, R. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15114236
Mukherjee, S., Grouza, V., Tchung, A., Even, A., Yaqubi, M., Tuznik, M., Cannon, T., Recinto, S. J., Gavino, C., Bourque, M.-J., et al. (2026) · PLoS Pathogens · doi:10.1371/journal.ppat.1014315 · Cited by 1
Wang, T., Tzeng, I., Chen, Y.-C., & Chen, M. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48070694
Complement dysregulation during the early phases of synucleinopathy
Khan, H., Gifford, M., Kordbacheh, A., Bury, A., Panoushek, S., Cole-Strauss, A., Kemp, C. J., Luk, K. C., Steece‐Collier, K., Kuhn, N. C., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-03057-8
Su, Y., Cai, S., Xu, Y., Xu, Q., Wang, Q., & Chen, X. (2026) · Clinics · doi:10.1016/j.clinsp.2026.101164
Metadata
- Authors
- Croisier, E., Moran, L. B., Dexter, D. T., Pearce, R. K., & Graeber, M. B.
- Affiliations
- Imperial College London (GB)
- Corresponding author
- Graeber, Manuel B
- ORCID
- Dexter, David T
- Venue
- Journal of Neuroinflammation
- Published
- 2005-06-03
- Volume
- 2
- Issue
- 1
- Pages
- 14-14
- ISSN
- 1742-2094 (ISSN-L)
- PMC
- PMC1177985
- OpenAlex
- W1822935226
- Cited by
- 414
- References
- 34
- Citations by year
- 2026: 15 · 2025: 18 · 2024: 44 · 2023: 24 · 2022: 25 · 2021: 38 · 2020: 44 · 2019: 18 · 2018: 22 · 2017: 15 · 2016: 13 · 2015: 19 · 2014: 18 · 2013: 19 · 2012: 11
- FWCI
- 7.36
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Journal of Neuroinflammation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Parkinson's UK (G-4028)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, microglial activation, substantia nigra, MHC class II expression, CD68, microglial phagocytosis, neuroinflammation, disease duration, neuronal loss, postmortem brain
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
